Hims & Hers Health reported strong Q1 '25 earnings, with 111% YoY sales growth and 38% subscriber growth. The company boasts over a 70% gross margin, 90% recurring revenue, and a compelling flywheel effect driven by machine learning and big data analytics. Risks include the untested business model, potential legal issues, and the complexity of international expansion, but the growth potential presented far outweighs these concerns.

Rockwell Automation raised its annual profit forecast on Wednesday after cost cuts helped boost margins in the second quarter, sending its shares up nearly 8% in premarket trade.

NEW YORK--(BUSINESS WIRE)--HG Vora Capital Management, LLC (together with its affiliates, “HG Vora”) today filed a complaint in the United States District Court for the Eastern District of Pennsylvania (the “Court”) against PENN Entertainment, Inc. (Nasdaq: PENN) (“PENN” or the “Company”) and its Board of Directors (the “Board”). The complaint alleges that PENN violated Pennsylvania's Business Corporation Law and the Board breached its fiduciary duties when it reduced the number of seats up for.

Dude, you're getting a Dell just doesn't have the same ring to it that it used to.

While robust channel sales drive QLYS' Q1 top-line performance, lowered expenses boost its earnings.

NEW YORK, NY / ACCESS Newswire / May 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Humana Inc. ("Humana Inc.") (NYSE:HUM) concerning possible violations of federal securities laws. On May 1, 2025, the U.S. Department of Justice announced it had filed a False Claims Act complaint against several health insurance companies and insurance broker organizations, including Humana.

NEW YORK, NY / ACCESS Newswire / May 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC Therapeutics, Inc.") (NASDAQ:PTCT) concerning possible violations of federal securities laws. PTC issued a press release on May 5, 2025, "announc[ing] results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease (HD) patients.

ConocoPhillips COP will release earnings results for the first quarter, before the opening bell on Thursday, May 8.

- Application represents milestone toward broadening patient access to inFoods IBS - inFoods® IBS pinpoints patient-specific foods that can trigger IBS symptoms like bloating, abdominal pain, diarrhea, and constipation IRVINE, Calif. , May 07, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company dedicated to the development of advanced diagnostic products, announced that the Company and its CLIA laboratory partner have submitted an application to the American Medical Association (AMA) CPT Editorial Panel requesting the assignment of a Proprietary Laboratory Analysis (PLA) code for the inFoods® IBS diagnostic test.

Bio-Techne on Wednesday beat Wall Street estimates for third-quarter profit, driven by growth in its unit that provides proteins, antibodies and other products for research and said it is launching a new share buyback program.

CSX Corporation, a key player in U.S. railroads, excels in logistics, focusing on efficiency, profitability, and reducing emissions under new CEO Joe Hinrichs. Despite revenue stagnation, CSX maintains high profitability through Precision Scheduled Railroading, cost optimization, and strategic investments in intermodal transport and infrastructure modernization. The company's shares are undervalued, trading at discounts compared to historical and peer averages, presenting a buying opportunity with a potential 16.31% price increase.

SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP has launched an investigation into whether the board members of AvidXchange Holdings, Inc. (NASDAQ: AVDX) breached their fiduciary duties in connection with the proposed sale of the Company to TPG Inc. (NASDAQ: TPG).

Jim Wyckoff has spent over 25 years involved with the stock, financial and commodity markets. He was a financial journalist with the FWN newswire service for many years, including stints as a reporter on the rough-and-tumble commodity futures trading floors in Chicago and New York.

MELBOURNE, Australia and SAN FRANCISCO, May 07, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that multiple oral and poster presentations related to Alterity's clinical programs in Multiple System Atrophy (MSA) will be featured at the 2025 International MSA Congress taking place May 9 - 11, 2025 in Boston, MA, USA. The Congress is presented by Mission MSA, a non-profit organization dedicated to improving the quality of life and building hope for people affected by MSA through support services, educational …

The market has been treading through rough waters in 2025, but several stocks in the entertainment industry are among the stars shining the brightest despite this. While many sectors have struggled to gain traction amid economic uncertainty and mixed earnings results, a select group of entertainment names has managed to stand out.

Energizer's fiscal second-quarter net sales and earnings decline year over year. The company lowers its fiscal 2025 guidance amid ongoing macroeconomic headwinds.

Yes, Consumer Staples are boring but nothing is boring about making money.

Ares Commercial Real Estate (ACRE) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of a loss of $0.07 per share. This compares to loss of $0.62 per share a year ago.

Entegris (ENTG) came out with quarterly earnings of $0.67 per share, missing the Zacks Consensus Estimate of $0.69 per share. This compares to earnings of $0.68 per share a year ago.

National Vision (EYE) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.29 per share. This compares to earnings of $0.30 per share a year ago.